1 de-3-phosphate dehydrogenase, Herceptin, and ReoPro.

2 peptides that were competitively eluted with ReoPro.

3  recent availability of c7E3 Fab (abciximab; ReoPro), a chimeric monoclonal antibody Fab fragment dir

4 rved with addition of the antibodies 7E3 and Reopro (abciximab) (10 microg/mL), accompanied by a 40%

5 rcutaneous Intervention Facilitated by Early Reopro Administration in Alsace) is a prospective, rando

6  beta3 integrin-specific Fab fragment, c7E3 (ReoPro), also inhibited the infectivity of HTN, SEO, and

7                We used chimeric (c) 7E3 Fab (ReoPro) and murine (m) 7E3 F(ab')(2) to elucidate the ro

8 (GP) IIb/IIIa receptor antagonist abciximab (ReoPro, c7E3 Fab) or conventional therapy.

9 d CAPTURE) have demonstrated that abciximab (ReoPro, chimeric 7E3 Fab) markedly reduces thrombotic ev

10                      In the Do Tirofiban and ReoPro Give Similar Efficacy Outcomes?

11 motivated the design of the Do Tirofiban and ReoPro Give Similar Efficacy Trial (TARGET) and the Glob

12 IIa receptor antagonist c7E3 Fab (abciximab; ReoPro) has been approved as an antithrombotic agent, an

13 ycoprotein IIb/IIIa blockade with abciximab (ReoPro) improves the clinical outcomes of percutaneous c

14 gh the effectiveness of abciximab (c7E3 Fab; ReoPro) in large populations of patients undergoing a pe

15 IIa receptor antagonist abciximab (c7E3 Fab, ReoPro) is approved for use in high-risk percutaneous tr

16  GP IIb/IIIa antagonist abciximab (c7E3 Fab; ReoPro) is effective in preventing thrombotic ischemic c

17  to monitor the effects of chimeric 7E3 Fab (ReoPro) on leukocyte and platelet activation and interac

18  antibodies such as c7E3 or its Fab fragment ReoPro prevents hantavirus entry.

19 dhesion (clopidogrel (Plavix) and abciximab (ReoPro), respectively).

20 nited States and other countries: abciximab (ReoPro; the Fab fragment of a chimeric human-mouse antib

21  foci to a greater extent than did 80 mug/ml ReoPro when preincubated with Vero E6 cells.